February 20, 2014—Bayer HealthCare Pharmaceuticals has limited sales of its widely used, genetically engineered multiple sclerosis (MS) drug Betaseron due to inability to meet demand, effective with orders received on or after Jan. 1, the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) announced on its website today. … [Read more...]
340B Provider Groups Urge HHS to Address Manufacturer Compliance
Coalition wants OPA funding boost used to police drugmakers more closelyFebruary 20, 2014—Health care providers in the 340B program are urging Health and Human Services (HHS) Secretary Kathleen Sebelius to use the program's $6 million funding boost to make sure that drug manufacturers aren't overcharging for covered outpatient drugs. … [Read more...]
340B Sales Totaled $7.5 Billion in 2013, Apexus Says
New figure indicates 340B's share of total U.S. drug sales is roughly 2%February 14, 2014—Pharmaceutical purchases through the 340B discount program were an estimated $7.5 billion in 2013, the 340B Prime Vendor Program (PVP) reports. Overall U.S. spending on pharmaceutical products in 2012, the most recent year for which data are available, stood at $326 billion, according to IMS Health Informatics Institute. Together, that figure and the new … [Read more...]
HRSA Issuing Regulation on 340B Rebates for AIDS Drug Assistance Programs
Announcement raises questions about 2005 policy guidanceFebruary 13, 2014—The Health Resources and Services Administration (HRSA) plans to propose a rule that will address the extent to which state AIDS Drug Assistance Programs (ADAPs) can collect full 340B rebates from drug manufacturers when the ADAPs pay premiums, copayments, and deductibles on health insurance that they may buy for ADAP clients. … [Read more...]
GAO Study Doesn’t Cite Drug Discounts as a Major Factor in Shortages
At hearing, some lawmakers indicate they will keep pressing the matterFebruary 11, 2014—Halts or slowdowns in manufacturing to address quality problems are the leading immediate cause of drug shortages, especially among generic sterile injectable products, the Government Accountability Office (GAO) concluded in a long awaited report yesterday. It recommended that the Food and Drug Administration (FDA) strengthen its internal controls over its … [Read more...]
OPA Focusing on 340B Drug Pricing Transparency and Accuracy
Pedley describes various initiatives in talk to stakeholdersFebruary 7, 2014—The Health Resources and Services (HRSA) Office of Pharmacy Affairs (OPA) is developing ways to improve 340B pricing transparency and accuracy by drug manufacturers, OPA Director Cmdr. Krista Pedley said yesterday during the 340B Coalition winter conference in San Diego. Pedley addressed the gathering of more than 900 stakeholders remotely from HRSA … [Read more...]
“Vigilant” 340B Contract Pharmacy Oversight Is Critical, Pedley Says
OPA director issued statement in Washington and spoke via video at 340B conference in San DiegoFebruary 6, 2014—Contract pharmacies "can enable 340B covered entities to expand the type and volume of care they provide to vulnerable patient populations," the director of the Health Resources and Services Administration (HRSA) Office of Pharmacy (OPA) said today in a public statement, but audits have shown that entities' oversight of contract pharmacies "did not always meet … [Read more...]